2019 Future of Periodontitis R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Periodontitis treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Periodontitis pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Periodontitis pipeline companies from advancing their products into Phase 3 or Phase 4.
Periodontitis Report Description-
The 2019 pipeline study on Periodontitis pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Periodontitis pipeline compounds.
The Periodontitis pipeline guide presents information on all active drugs currently being developed for Periodontitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Periodontitis pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Periodontitis drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Periodontitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Periodontitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Periodontitis pipeline report includes-
Periodontitis Report Description-
The 2019 pipeline study on Periodontitis pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Periodontitis pipeline compounds.
The Periodontitis pipeline guide presents information on all active drugs currently being developed for Periodontitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Periodontitis pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Periodontitis drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Periodontitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Periodontitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Periodontitis pipeline report includes-
- An overview of Periodontitis disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Periodontitis pipeline
- Company wise list of Periodontitis pipeline
- Mechanism of Action wise Periodontitis pipeline
- For each pipeline candidate, the following details are provided
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Periodontitis pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Periodontitis pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Periodontitis pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL PERIODONTITIS PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Periodontitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Periodontitis pipeline, H1- 2019
3.5 Mechanism of Action wise Periodontitis Pipeline Candidates
4 AMYNDAS PHARMACEUTICALS LLC PERIODONTITIS PIPELINE DETAILS
4.1 Amyndas Pharmaceuticals LLC Business Profile
4.2 Amyndas Pharmaceuticals LLC Periodontitis Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 CSL LTD PERIODONTITIS PIPELINE DETAILS
5.1 CSL Ltd Business Profile
5.2 CSL Ltd Periodontitis Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 GEISTLICH PHARMA AG PERIODONTITIS PIPELINE DETAILS
6.1 Geistlich Pharma AG Business Profile
6.2 Geistlich Pharma AG Periodontitis Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 GLYCOMIRA THERAPEUTICS INC PERIODONTITIS PIPELINE DETAILS
7.1 GlycoMira Therapeutics Inc Business Profile
7.2 GlycoMira Therapeutics Inc Periodontitis Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 GUANGZHOU SALIAI STEM CELL SCIENCE AND TECHNOLOGY CO LTD PERIODONTITIS PIPELINE DETAILS
8.1 Guangzhou Saliai Stem cell Science and Technology Co Ltd Business Profile
8.2 Guangzhou Saliai Stem cell Science and Technology Co Ltd Periodontitis Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 KUHNIL PHARMACEUTICAL CO LTD PERIODONTITIS PIPELINE DETAILS
9.1 Kuhnil Pharmaceutical Co Ltd Business Profile
9.2 Kuhnil Pharmaceutical Co Ltd Periodontitis Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 NOVEOME BIOTHERAPEUTICS INC PERIODONTITIS PIPELINE DETAILS
10.1 Noveome Biotherapeutics Inc Business Profile
10.2 Noveome Biotherapeutics Inc Periodontitis Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 TGV LABORATORIES INC PERIODONTITIS PIPELINE DETAILS
11.1 TGV Laboratories Inc Business Profile
11.2 TGV Laboratories Inc Periodontitis Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. LATEST PERIODONTITIS DRUG PIPELINE DEVELOPMENTS, 2019
13. APPENDIX
13.1 About Us
13.2 Sources and Methodology
13.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL PERIODONTITIS PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Periodontitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Periodontitis pipeline, H1- 2019
3.5 Mechanism of Action wise Periodontitis Pipeline Candidates
4 AMYNDAS PHARMACEUTICALS LLC PERIODONTITIS PIPELINE DETAILS
4.1 Amyndas Pharmaceuticals LLC Business Profile
4.2 Amyndas Pharmaceuticals LLC Periodontitis Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 CSL LTD PERIODONTITIS PIPELINE DETAILS
5.1 CSL Ltd Business Profile
5.2 CSL Ltd Periodontitis Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 GEISTLICH PHARMA AG PERIODONTITIS PIPELINE DETAILS
6.1 Geistlich Pharma AG Business Profile
6.2 Geistlich Pharma AG Periodontitis Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 GLYCOMIRA THERAPEUTICS INC PERIODONTITIS PIPELINE DETAILS
7.1 GlycoMira Therapeutics Inc Business Profile
7.2 GlycoMira Therapeutics Inc Periodontitis Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 GUANGZHOU SALIAI STEM CELL SCIENCE AND TECHNOLOGY CO LTD PERIODONTITIS PIPELINE DETAILS
8.1 Guangzhou Saliai Stem cell Science and Technology Co Ltd Business Profile
8.2 Guangzhou Saliai Stem cell Science and Technology Co Ltd Periodontitis Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 KUHNIL PHARMACEUTICAL CO LTD PERIODONTITIS PIPELINE DETAILS
9.1 Kuhnil Pharmaceutical Co Ltd Business Profile
9.2 Kuhnil Pharmaceutical Co Ltd Periodontitis Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 NOVEOME BIOTHERAPEUTICS INC PERIODONTITIS PIPELINE DETAILS
10.1 Noveome Biotherapeutics Inc Business Profile
10.2 Noveome Biotherapeutics Inc Periodontitis Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 TGV LABORATORIES INC PERIODONTITIS PIPELINE DETAILS
11.1 TGV Laboratories Inc Business Profile
11.2 TGV Laboratories Inc Periodontitis Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. LATEST PERIODONTITIS DRUG PIPELINE DEVELOPMENTS, 2019
13. APPENDIX
13.1 About Us
13.2 Sources and Methodology
13.3 Contact Information
